Page last updated: 2024-11-07

4-nitrophenylglycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Nitrophenylglycerol (4-NPG) is a synthetic compound that exhibits various pharmacological effects, including anti-inflammatory, analgesic, and anti-cancer activities. Its synthesis involves the reaction of glycerol with 4-nitrophenol under specific conditions. The compound has been investigated for its potential therapeutic applications in various diseases, including rheumatoid arthritis and cancer. 4-NPG has been shown to inhibit the production of pro-inflammatory cytokines and chemokines, thus reducing inflammation. Moreover, its analgesic effects are attributed to its ability to block pain signals in the central nervous system. The anti-cancer properties of 4-NPG are related to its ability to induce apoptosis in cancer cells. Research on 4-NPG focuses on understanding its mechanisms of action, optimizing its synthesis and formulation, and exploring its potential as a drug candidate for various diseases.'

4-nitrophenylglycerol: antiswarming agent for bacterial cultures [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID102764
CHEMBL ID1836141
SCHEMBL ID2374452
MeSH IDM0065734

Synonyms (27)

Synonym
OPREA1_308530
1-(4-nitrophenyl)glycerol, crystalline
p-nitrophenylglycerol
1-(4-nitrophenyl)glycerol, 99%
MAYBRIDGE1_002064
1-(4-nitrophenyl)glycerol
N-2750
4-nitrophenylglycerol
HMS547F18
1-(4-nitrophenyl)-1,2,3-propanetriol
1-(4-nitrophenyl)propane-1,2,3-triol
CHEMBL1836141
2207-68-3
einecs 218-624-9
para-nitrophenylglycerol
1,2,3-propanetriol, (4-nitrophenyl)-
FT-0605767
AKOS015913436
methyl17-methyloctadecanoate
SCHEMBL2374452
BTB 12954
1,2,3-propanetriol, 1-(4-nitrophenyl)-
mfcd00017037
AS-62950
DTXSID60944693
D87898
CS-0312875
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID620929Antibacterial activity against erythromycin-lincomycin resistant Bacillus subtilis NCIB 3610 DS64 harboring hag deletion mutant assessed as inhibition of surface colony-spreading at 75 ug/ml after 24 hrs relative to control2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
New inhibitors of colony spreading in Bacillus subtilis and Bacillus anthracis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (23.08)18.7374
1990's4 (30.77)18.2507
2000's5 (38.46)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.75 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]